The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

American Academy of Psychiatric Pharmacists
April 27th – 30th 2025, Salt Lake City, UT
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Study Retention Rates in the Olanzapine/Samidorphan Phase 3 Clinical Program
AUTHOR(S)

René S. Kahn,1 Christina Arevalo,2 Marni E. Harris,2 David McDonnell3

View poster
Bipolar Disorder
Schizophrenia
Schizophrenia
ENCORE POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients With Schizophrenia Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane, MD,1 Andrea B. Barthel, MS,2 Chenxue Liang,2 Zhengfan Wang,2 Elizabeth S. Nagelhout,2 Lauren N. Strand, PhD, MS,3 Michael J. Doane, PhD,3 Regina Grebla, PhD3

View poster
Schizophrenia